Physician and Pharmacist Understanding of the Risk of Urinary Retention with Retigabine (Ezogabine): A REMS Assessment Survey

Background The Risk Evaluation and Mitigation Strategy (REMS) for retigabine/ezogabine (RTG/EZG) required an evaluation of the effectiveness of the communication plan to communicate about the risks with use of RTG/EZG. Objective GlaxoSmithKline conducted a survey to assess understanding of the risk...

Full description

Saved in:

Bibliographic Details
Published in:	Drugs - real world outcomes Vol. 2; no. 4; pp. 335 - 344
Main Authors:	Ishihara, Lianna, Beck, Melissa, Travis, Sara, Akintayo, Olusegun, Brickel, Neil
Format:	Journal Article
Language:	English
Published:	Cham Springer International Publishing 01.12.2015 Springer Nature B.V
Subjects:	Communication Convulsions & seizures Demographics Drug stores Epilepsy FDA approval Information dissemination Internal Medicine Medicine Medicine & Public Health Pharmacists Pharmacology/Toxicology Pharmacotherapy Physicians Questionnaires Short Communication Urinary retention United States > US Sales Representative Communication Plan Retigabine Urinary Retention Product Label
ISSN:	2199-1154, 2198-9788
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!